Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

DaBomb Protein Biotech Corp. (6578.TWO)

17.10
-0.25
(-1.44%)
At close: April 30 at 1:30:21 PM GMT+8
Loading Chart for 6578.TWO
  • Previous Close 17.35
  • Open 17.25
  • Bid 17.10 x --
  • Ask 17.20 x --
  • Day's Range 17.10 - 17.30
  • 52 Week Range 15.20 - 33.90
  • Volume 70,108
  • Avg. Volume 131,563
  • Market Cap (intraday) 1.163B
  • Beta (5Y Monthly) 0.54
  • PE Ratio (TTM) 100.59
  • EPS (TTM) 0.17
  • Earnings Date --
  • Forward Dividend & Yield 0.51 (2.98%)
  • Ex-Dividend Date Jul 30, 2024
  • 1y Target Est --

DaBomb Protein Biotech Corp. engages in the development of antibiotics alternatives in animal health industry. It offers plant protein, including DaBomb-P (Aqua) and DaBomb-P (Livestock); antibiotics alternatives, such as DBT-100 HT and DBT-100 LS; and pet care products comprising Liqui-TIDE bandages. The company was formerly known as DaBomb Protein Corp. and changed its name to DaBomb Protein Biotech Corp. in October 2023. DaBomb Protein Biotech Corp. was founded in 2001 and is based in Tainan, Taiwan.

www.dabombprotein.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6578.TWO

View More

Performance Overview: 6578.TWO

Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6578.TWO
13.64%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
12.16%

1-Year Return

6578.TWO
36.72%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
0.79%

3-Year Return

6578.TWO
15.03%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
21.96%

5-Year Return

6578.TWO
4.57%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
84.09%

Compare To: 6578.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6578.TWO

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    1.16B

  • Enterprise Value

    1.03B

  • Trailing P/E

    100.59

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.46

  • Price/Book (mrq)

    1.07

  • Enterprise Value/Revenue

    3.04

  • Enterprise Value/EBITDA

    29.34

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.44%

  • Return on Assets (ttm)

    -0.08%

  • Return on Equity (ttm)

    1.14%

  • Revenue (ttm)

    337.82M

  • Net Income Avi to Common (ttm)

    11.64M

  • Diluted EPS (ttm)

    0.17

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    253.59M

  • Total Debt/Equity (mrq)

    15.43%

  • Levered Free Cash Flow (ttm)

    8.9M

Research Analysis: 6578.TWO

View More

Company Insights: 6578.TWO

Research Reports: 6578.TWO

View More

People Also Watch